PT3452454T - Moduladores da via integrada ao stresse - Google Patents
Moduladores da via integrada ao stresseInfo
- Publication number
- PT3452454T PT3452454T PT177242054T PT17724205T PT3452454T PT 3452454 T PT3452454 T PT 3452454T PT 177242054 T PT177242054 T PT 177242054T PT 17724205 T PT17724205 T PT 17724205T PT 3452454 T PT3452454 T PT 3452454T
- Authority
- PT
- Portugal
- Prior art keywords
- modulators
- integrated stress
- stress pathway
- pathway
- integrated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332284P | 2016-05-05 | 2016-05-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3452454T true PT3452454T (pt) | 2020-10-12 |
Family
ID=58710114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177242054T PT3452454T (pt) | 2016-05-05 | 2017-05-05 | Moduladores da via integrada ao stresse |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10864196B2 (pt) |
| EP (2) | EP3452454B1 (pt) |
| JP (2) | JP6869331B2 (pt) |
| CN (1) | CN109641853A (pt) |
| AR (1) | AR108394A1 (pt) |
| AU (1) | AU2017260363B2 (pt) |
| CA (1) | CA3023161A1 (pt) |
| ES (1) | ES2821790T3 (pt) |
| PT (1) | PT3452454T (pt) |
| TW (1) | TW201808914A (pt) |
| UY (1) | UY37231A (pt) |
| WO (1) | WO2017193030A1 (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| CN112713985B (zh) | 2017-05-05 | 2022-03-08 | 华为技术有限公司 | 传输信号的方法和装置 |
| BR112019024155A2 (pt) * | 2017-05-15 | 2020-06-02 | Recurium Ip Holdings, Llc | Compostos analgésicos |
| WO2018225093A1 (en) * | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN110730777A (zh) * | 2017-06-07 | 2020-01-24 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4通路抑制剂的化学化合物 |
| IL301709A (en) | 2017-08-09 | 2023-05-01 | Denali Therapeutics Inc | Compounds, preparations and methods |
| BR112020008834A2 (pt) | 2017-11-02 | 2020-12-22 | Calico Life Sciences Llc | Moduladores da via de estresse integrada |
| WO2019090081A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2019090078A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP2021508336A (ja) | 2017-12-13 | 2021-03-04 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路の阻害剤 |
| WO2019183589A1 (en) * | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| EP3801522A4 (en) | 2018-06-05 | 2022-06-01 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY INHIBITORS |
| AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US20220177438A1 (en) * | 2019-02-13 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CR20210426A (es) * | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
| BR112021020106A2 (pt) * | 2019-04-23 | 2021-12-07 | Evotec Int Gmbh | Moduladores da via de resposta ao estresse inte-grado |
| EP3959198A1 (en) | 2019-04-23 | 2022-03-02 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CN114206848A (zh) | 2019-04-30 | 2022-03-18 | 卡里科生命科学有限责任公司 | 作为整合应激通路的调节剂的被取代的环烷基化合物 |
| EP3982965A4 (en) | 2019-06-12 | 2023-01-25 | Praxis Biotech LLC | INTEGRATED STRESS RESPONSE PATHWAY MODULATORS |
| CA3155287A1 (en) | 2019-09-26 | 2021-04-01 | Novartis Ag | Antiviral pyrazolopyridinone compounds |
| CN114980887A (zh) | 2019-12-20 | 2022-08-30 | 特纳亚治疗股份有限公司 | 氟代烷基-噁二唑及其用途 |
| US20230125481A1 (en) | 2020-01-28 | 2023-04-27 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EP4117780A1 (en) | 2020-03-11 | 2023-01-18 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| CA3195293A1 (en) | 2020-10-22 | 2022-04-28 | Holly Victoria Atton | Modulators of the integrated stress response pathway |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| KR20230110511A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162A (en) | 1837-04-17 | Island | ||
| US5212A (en) | 1847-07-31 | Richard m | ||
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| UA80459C2 (en) * | 2002-12-20 | 2007-09-25 | Merck & Co Inc | Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
| JP2007517868A (ja) | 2004-01-07 | 2007-07-05 | アストラゼネカ アクチボラグ | 治療薬ｉ |
| WO2006074330A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| EP1924553A1 (en) | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| JP5301999B2 (ja) * | 2005-10-31 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｅｔｐ阻害薬 |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| EP2968347B1 (en) * | 2013-03-15 | 2023-08-02 | The Regents of the University of California | Modulators of the eif2alpha pathway |
| US20160318856A1 (en) * | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| JP7049276B2 (ja) * | 2016-06-24 | 2022-04-06 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピンおよびその結合体 |
-
2017
- 2017-05-04 TW TW106114862A patent/TW201808914A/zh unknown
- 2017-05-05 EP EP17724205.4A patent/EP3452454B1/en active Active
- 2017-05-05 AU AU2017260363A patent/AU2017260363B2/en not_active Expired - Fee Related
- 2017-05-05 CA CA3023161A patent/CA3023161A1/en not_active Abandoned
- 2017-05-05 US US16/098,950 patent/US10864196B2/en active Active
- 2017-05-05 ES ES17724205T patent/ES2821790T3/es active Active
- 2017-05-05 PT PT177242054T patent/PT3452454T/pt unknown
- 2017-05-05 AR ARP170101182A patent/AR108394A1/es unknown
- 2017-05-05 EP EP20184319.0A patent/EP3778575A1/en not_active Withdrawn
- 2017-05-05 JP JP2019510574A patent/JP6869331B2/ja active Active
- 2017-05-05 CN CN201780042067.3A patent/CN109641853A/zh active Pending
- 2017-05-05 UY UY0001037231A patent/UY37231A/es not_active Application Discontinuation
- 2017-05-05 WO PCT/US2017/031352 patent/WO2017193030A1/en unknown
-
2020
- 2020-05-28 US US16/885,766 patent/US20210113532A1/en not_active Abandoned
-
2021
- 2021-04-13 JP JP2021067440A patent/JP2021107415A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10864196B2 (en) | 2020-12-15 |
| JP6869331B2 (ja) | 2021-05-12 |
| TW201808914A (zh) | 2018-03-16 |
| CN109641853A (zh) | 2019-04-16 |
| US20190142806A1 (en) | 2019-05-16 |
| AU2017260363B2 (en) | 2021-12-02 |
| AR108394A1 (es) | 2018-08-15 |
| UY37231A (es) | 2017-11-30 |
| WO2017193030A1 (en) | 2017-11-09 |
| ES2821790T3 (es) | 2021-04-27 |
| ES2821790T8 (es) | 2022-01-03 |
| EP3452454A1 (en) | 2019-03-13 |
| EP3452454B1 (en) | 2020-07-08 |
| JP2021107415A (ja) | 2021-07-29 |
| CA3023161A1 (en) | 2017-11-09 |
| JP2019515042A (ja) | 2019-06-06 |
| AU2017260363A1 (en) | 2018-11-15 |
| EP3778575A1 (en) | 2021-02-17 |
| US20210113532A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274369A (en) | Combined pressure pathway modulators | |
| PT3452454T (pt) | Moduladores da via integrada ao stresse | |
| IL274405A (en) | Combined pressure pathway modulators | |
| FI3452448T3 (fi) | Integroidun stressivastereitin modulaattoreita | |
| IL274368A (en) | Combined pressure pathway modulators | |
| IL274406A (en) | Combined pressure pathway modulators | |
| IL274367A (en) | Combined pressure pathway modulators | |
| IL283582A (en) | ror - gamma modulators | |
| IL262303A (en) | Modulators of nlrp3 | |
| HK1256599A1 (zh) | ROR-γ的調節劑 | |
| IL282153A (en) | Prodrugs modulate integrated stress pathways | |
| PL3303291T3 (pl) | Modulatory ROR-gamma | |
| PL3303293T3 (pl) | Modulatory ROR-gamma | |
| PL3303290T3 (pl) | Modulatory ROR-gamma | |
| IL271935A (en) | NLRP3 modulators | |
| IL266265A (en) | Functional chocolate | |
| IL266261A (en) | ror-gamma modulators | |
| PL3319942T3 (pl) | MODULATORY ROR-GAMMA (RORγ) | |
| GB201716468D0 (en) | Modulators | |
| GB2563095B (en) | Modulators | |
| TWI844006B (zh) | 整合應激途徑之調節劑 | |
| GB201702926D0 (en) | Modulators | |
| GB2549084B (en) | Fixing | |
| GB201609238D0 (en) | Stress response | |
| GB201614045D0 (en) | Microcapsules |